Please complete as man	y details as	possible and forward	within one	business day	y to:
------------------------	--------------	----------------------	------------	--------------	-------

Program Details											
Form Completed By					Name of Program: TREATMENT OF HCV PATIENTS WITH						
Print Name: Tsovinar Galstyan					DONATED "SOVALDI" MEDICINE IN THE REPUBLIC OF ARMENIA						
					Name of Organisation: : "NORK" REPUBLICAN INFECTIOUS CLINICAL HOSPITAL						
Signature:						0					
Telephone Number:				Dat	Date aware of Safety Information: 13/07/2017						
Fax No/Email: galstyan.tsovinar@mail.ru				Cor	Country of Occurrence of Safety Information: ARMENIA						
Patient Deta	ils										
<b>DOB</b> : 29/	04/1964 (or year of birth):		Sex: N	⁄lale ☑	Female	<b>:</b> 🗆	Init	ials: S.S.	Δ	Age:	49
Drug Details	(Provide additional drugs on a se	eparate page)									
Lot/Batch No	Reason For Taking	Stop Date (or (DD/MON/Y			t Date DN/YYYY)	Route		Dose	ose Drug Nar		lame
TZDPD	НЕР С	On-going		05/0	6/2017			400MG	SOVALDI		OI
		On-going		05/0	6/2017	PO		60MG DA		DAKLATASVIR	
				03/0	7/2017	РО		1200		RIBAV	'IRIN
Safety Information Details: Please provide a short summary of the adverse event(s) (AE) or other safety information (e.g. reports such as pregnancy, death, hospitalization, overdose, misuse, abuse, medication error, lack of effect, off-label use, occupational exposure, AEs associated with product complaints or AEs in an infant following exposure from breastfeeding). Please include the start and stop dates and the outcome of the event(s) or confirm if the event(s) is/are still ongoing. Please also provide any treatment given to treat the event(s), any relevant medical history and for reports of death include the date of death – continue on another page if necessary.  During the treatment patient experienced tingling in right side of hypochondria, palm skin exfoliation, weight gain (approximately 3 kg in 1.5 month). Reactions were resolved after withdrawal of Ribavirin.											
•	formation previously been rep Yes □ No ☑	•	ulatory	Doe drug				hat the event(s		ossibly r	related to the
Reporter Details (i.e. who notified you of the above safety information?)											
Is the Reporter a: Doctor   Norse  Normalithating at professional (e.g. patient, relative)*  If the Reporter is a Healthcare Professional (HCP) and they are willing to provide us with their contact information, please record below											
*If the Reporter is a Non-healthcare professional, please confirm if they are willing to provide contact information for their HCP:  Yes     Please record HCP details be bw)   No											
Yes □ (P lease record H C P deta ils be bw) No □  HCP Address HCP Name:											
First Line:											
HCP Telephone No/FAX No:											
Town/City:				HC	HCP Email:						
County/State:											
Postcode/Zip code:											

Please be aware that information provided to the Ministry of Labour, Health and Social Affairs of Georgia(MoLHSA) relating to you, may be used to comply with applicable laws and regulations. By providing us with information you are consenting to the control and processing of this personal or sensitive data by MoLHSA in accordance with applicable data protection laws and the MoLHSA privacy policy.